Le Lézard
Classified in: Health, Science and technology
Subject: FDA

InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL


BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL).

Orelabrutinib is a highly selective BTK inhibitor targeting both B-cell malignancy and autoimmune diseases. On Dec. 25, 2020, orelabrutinib was approved by the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) /small lymphocytic lymphoma (R/R SLL), and the treatment of patients with R/R MCL.

Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare said, "We are very proud that orelabrutinib was granted BTD after obtaining Orphan Drug Designation. We will continue to uphold the concept of 'Science drives innovation for the benefit of patients' and accelerate clinical trials for multiple indications of orelabrutinib in China and the rest of the world to benefit patients worldwide."

Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of drugs that are intended to treat serious or life-threatening conditions and have demonstrated preliminary clinical evidence of substantial improvement over existing therapies.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

Contact




Media                                                                                      

Investor Relations

Chunhua Lu                                                                            


86-10-66609879                                                                        

86-10-66609999

chunhua.lu@innocarepharma.com                                            

ir@innocarepharma.com

 

SOURCE Innocare


These press releases may also interest you

at 06:05
Jumio, the leading provider of AI-powered end-to-end identity verification, eKYC and AML solutions, today announced the launch of an intuitive no-code orchestration layer for its KYX Platform that unifies an entire set of risk and fraud detection...

at 06:05
Merck , known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the European Medicines Agency (EMA) has initiated a rolling review for molnupiravir, an investigational oral antiviral medicine, for the...

at 06:05
Mojenta, the first and only B2B tech marketing agency, announced today it has successfully completed 11 years in business. In that time, Mojenta has serviced nearly 300 telecom carriers, technology service distributors, managed services providers...

at 06:03
DevOps Institute (https://www.devopsinstitute.com/), a global professional association for advancing and certifying the humans of DevOps, today announced an exclusive distributor agreement and strategic partnership with Top Out Human Capital to serve...

at 06:02
Following the successful and well-received Allograft line, Neoss is excited to announce the addition of NeoGenix XPtm this autumn to our existing product portfolio. NeoGenix XPtm is a safe and clinically proven natural bone substitute, that closer...

at 06:01
ADS-TEC Energy GmbH ("ADS-TEC Energy" or "the Company"), a global leader in battery-buffered ultrafast charging technology, and Polar Structure AB ("Polar"), a platform for managing infrastructure related assets, today announced that they have...



News published on 28 june 2021 at 04:02 and distributed by: